Pharsight

Drugs that contain Irinotecan Hydrochloride

1. Camptosar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6403569 PFIZER INC Method for treating cancer using camptothecin derivatives and 5-fluorouracil
Apr, 2020

(3 years ago)

US6794370 PFIZER INC Method for treating cancer using camptothecin derivatives and 5-fluorouracil
May, 2020

(3 years ago)

US6403569

(Pediatric)

PFIZER INC Method for treating cancer using camptothecin derivatives and 5-fluorouracil
Oct, 2020

(3 years ago)

US6794370

(Pediatric)

PFIZER INC Method for treating cancer using camptothecin derivatives and 5-fluorouracil
Nov, 2020

(3 years ago)

Market Authorisation Date: 14 June, 1996

Treatment: Use in combination with 5-fluorouracil and leucovorin for the treatment of metastatic colorectal cancer where the dose of leucovorin is at least 200mg per square meter; Use of irinotecan in combinatio...

Dosage: INJECTABLE;INJECTION

How can I launch a generic of CAMPTOSAR before it's drug patent expiration?
More Information on Dosage

CAMPTOSAR family patents

Family Patents

2. Onivyde patents expiration

ONIVYDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9782349 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 11 days from now)

US8992970 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 11 days from now)

US9724303 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 11 days from now)

US10722508 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 11 days from now)

US8329213 IPSEN INC Liposomes useful for drug delivery
Jan, 2027

(2 years from now)

US8147867 IPSEN INC Liposomes useful for drug delivery
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703181 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 11 days from now)

US9730891 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 11 days from now)

US9339497 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US9717724 IPSEN INC Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(9 years from now)

US9492442 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US11369597 IPSEN INC Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(9 years from now)

US10980795 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US9452162 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US9364473 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US10993914 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(12 years from now)

US10456360 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-463) Feb 13, 2031
New Indication(I-932) Feb 13, 2027
Orphan Drug Exclusivity(ODE-99) Oct 22, 2022
Orphan Drug Exclusivity(ODE) Oct 22, 2022
New Product(NP) Oct 22, 2018

Market Authorisation Date: 22 October, 2015

Treatment: Treatment of pancreatic cancer; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of...

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage

ONIVYDE family patents

Family Patents